NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

MRK

Merck & Co Inc

Jul 01 • 04:00PM ET

81.81

Dollar change +2.65
Percentage change 3.35	%

Healthcare • Drug Manufacturers - General • USA • NYSE

Peers: PFE AZN NVS BMY JNJ AMGN ABBV GSK LLY SNY

| Held by: VTI VOO SCHD SPY IVV VTV XLV VIG VYM DGRO

Scroll to Statements

Index	DJIA, S&P 500	P/E	11.91	EPS (ttm)	6.87	Insider Own	0.07%	Shs Outstand	2.52B	Perf Week	1.86%
Market Cap	205.43B	Forward P/E	8.42	EPS next Y	9.72	Insider Trans	-0.19%	Shs Float	2.51B	Perf Month	6.47%
Enterprise Value	231.01B	PEG	1.02	EPS next Q	2.04	Inst Own	80.31%	Short Float	1.43%	Perf Quarter	-8.86%
Income	17.43B	P/S	3.22	EPS this Y	16.22%	Inst Trans	0.43%	Short Ratio	2.15	Perf Half Y	-18.08%
Sales	63.78B	P/B	4.26	EPS next Y	9.30%	ROA	15.78%	Short Interest	35.80M	Perf YTD	-17.76%
Book/sh	19.21	P/C	22.02	EPS next 5Y	11.64%	ROE	39.31%	52W High	129.93 -37.04%	Perf Year	-36.98%
Cash/sh	3.72	P/FCF	12.06	EPS past 3/5Y	9.42% 12.04%	ROIC	21.31%	52W Low	73.31 11.59%	Perf 3Y	-12.16%
Dividend Est.	3.13 (3.83%)	EV/EBITDA	8.66	Sales past 3/5Y	9.36% 6.55%	Gross Margin	74.68%	Volatility	2.48% 2.36%	Perf 5Y	13.08%
Dividend TTM	3.20 (3.91%)	EV/Sales	3.62	EPS Y/Y TTM	654.93%	Oper. Margin	34.71%	ATR (14)	2.03	Perf 10Y	45.35%
Dividend Ex-Date	Jun 16, 2025	Quick Ratio	1.16	Sales Y/Y TTM	4.40%	Profit Margin	27.33%	RSI (14)	58.88	Recom	1.88
Dividend Gr. 3/5Y	5.73% 6.66%	Current Ratio	1.41	EPS Q/Q	7.20%	SMA20	2.70%	Beta	0.40	Target Price	102.10
Payout	46.32%	Debt/Eq	0.72	Sales Q/Q	-1.20%	SMA50	3.36%	Rel Volume	1.29	Prev Close	79.16
Employees	75000	LT Debt/Eq	0.69	Earnings	Apr 24 BMO	SMA200	-12.58%	Avg Volume	16.63M	Price	81.81
IPO	Jun 15, 1946	Option/Short	Yes / Yes	EPS/Sales Surpr.	4.09% 1.24%	Trades		Volume	21,435,063	Change	3.35%

Date	Action	Analyst	Rating Change	Price Target Change
May-14-25	Downgrade	Citigroup	Buy → Neutral	$84
Apr-22-25	Initiated	Cantor Fitzgerald	Neutral	$85
Feb-18-25	Downgrade	Deutsche Bank	Buy → Hold	$128 → $105
Feb-10-25	Downgrade	TD Cowen	Buy → Hold	$121 → $100
Jan-08-25	Downgrade	Truist	Buy → Hold	$110
Dec-20-24	Downgrade	BMO Capital Markets	Outperform → Market Perform	$136 → $105
Dec-10-24	Resumed	BofA Securities	Buy	$121
Dec-04-24	Upgrade	HSBC Securities	Hold → Buy	$130
Nov-15-24	Initiated	Wolfe Research	Peer Perform
Nov-11-24	Downgrade	Daiwa Securities	Buy → Neutral
Oct-17-24	Initiated	Bernstein	Mkt Perform	$115
Mar-11-24	Downgrade	Societe Generale	Hold → Sell	$104
Jan-04-24	Upgrade	TD Cowen	Market Perform → Outperform	$125 → $135
Nov-09-23	Initiated	Deutsche Bank	Buy	$115
Oct-27-23	Upgrade	BMO Capital Markets	Market Perform → Outperform	$132
Oct-20-23	Upgrade	UBS	Neutral → Buy	$117 → $122
Jul-14-23	Initiated	HSBC Securities	Hold	$123
Apr-13-23	Upgrade	Citigroup	Neutral → Buy	$105 → $130
Mar-28-23	Downgrade	Societe Generale	Buy → Hold
Mar-13-23	Downgrade	Wells Fargo	Overweight → Equal Weight	$120 → $115

Show Previous Ratings

Today 12:10PM	Will Merck (MRK) Beat Estimates Again in Its Next Earnings Report? (Zacks)
09:35AM	Pfizer's Strong Late-Stage Pipeline Can Drive Long-Term Growth (Zacks)
06:45AM	Merck to Hold Second-Quarter 2025 Sales and Earnings Conference Call July 29 (Business Wire)
Jun-30-25 09:50AM	BMY Loses 16.3% YTD: Should You Buy, Sell or Hold the Stock? (Zacks)
07:55AM	Gilead extends gains after Supreme Court upheld an Obamacare provision (Investing.com)
10:09AM	Loading…
Jun-28-25 10:09AM	3 Absurdly Cheap Stocks Ready for a Breakout (Motley Fool)
02:15AM	Should You Count on MRK for Steady Passive Income? (Insider Monkey)
Jun-27-25 09:35AM	Cancer Vaccine (Preventative, Therapeutic) Market Research 2025 with Analyst Recommendations-Leveraging AI and Bioinformatics for Precision Development / Pursue Fast-Track and Orphan Drug Designations (GlobeNewswire)
Jun-26-25 05:50PM	Merck (MRK) Stock Falls Amid Market Uptick: What Investors Need to Know (Zacks)
02:28PM	The Anti-Vax Movement Solidifies Control of the CDC's Vaccine Committee (Barrons.com)
01:54PM	Mercks RSV shot for infants gets key approval despite RFK Jr.s panel shakeup (FastCompany)
01:39PM	ACIP Recommends Use of Mercks ENFLONSIA (clesrovimab-cfor) for Prevention of Respiratory Syncytial Virus (RSV) Lower Respiratory Tract Disease in Infants Younger than 8 Months of Age Born During or Entering Their First RSV Season (Business Wire)
09:47AM	Will MRK's Growing Pipeline Help Navigate the Looming Keytruda LOE? (Zacks)
09:11AM	Europe Proteomics Research Report 2025: Market Insights, Competitive Landscape and Forecasts 2024-2034 Featuring Biognosys, DiaSorin, Merck, Oxford Expression Technologies (GlobeNewswire)
06:45AM	2 Stocks Too Cheap to Ignore at These Prices (Motley Fool)
10:02AM	Loading…
Jun-25-25 10:02AM	Will New Drugs Enable BMY to Offset the Impact of Generic Competition? (Zacks)
09:59AM	Merck Moves Past 50-Day Average: How to Play MRK Stock Now (Zacks)
04:29AM	Jefferies Maintains a Buy Rating on Merck & Co. (MRK), Keeps the PT Unchanged (Insider Monkey)
Jun-24-25 12:20PM	MRK's Winrevair Phase III Study in Newly Diagnosed PAH Meets Goal (Zacks)
10:25AM	Pfizer to Face Several Headwinds: Can It Successfully Navigate Them? (Zacks)
09:56AM	Sanofi Trades Below 50 & 200-Day Moving Averages: Time to Buy the Dip? (Zacks)
09:40AM	EXEL Stock Rises on Positive Data From Colorectal Cancer Study (Zacks)
08:22AM	Will AbbVie's Growing Oncology Portfolio Aid Top-line Growth? (Zacks)
07:05AM	NeoGenomics Appoints Dr. Marjorie Green to Board of Directors (Business Wire)
06:45AM	Merck to Hold Investor Event to Highlight Advancing Research Pipeline for HIV Treatment and Prevention (Business Wire)
06:13AM	Brain Cancer Market Research Report 2025-2035 \| Growing Shifts Toward Targeted Therapies and Immunotherapy Over Traditional Methods (GlobeNewswire)
06:02AM	Allergic Rhinitis Market Report 2025-2035 \| Innovative Drug Classes and Regional Trends Propel Expansion (GlobeNewswire)
03:39AM	How a Big Pharma veteran looks to stand out in biotech as a unique drug hunter (Pharma Voice)
Jun-23-25 10:46PM	Merck Poised to Deliver Strong Results and Steady Dividend Growth (Insider Monkey)
06:45AM	Merck Announces Phase 3 HYPERION Study of WINREVAIR (sotatercept-csrk) Met Primary Endpoint in Recently Diagnosed Adults with Pulmonary Arterial Hypertension (PAH) (Business Wire)
02:06PM	Loading…
Jun-20-25 02:06PM	The 5 Most Interesting Analyst Questions From Merck's Q1 Earnings Call (StockStory)
08:00AM	Why CareTrust, Merck, And Allete Are Winners For Passive Income (Benzinga)
Jun-19-25 09:47AM	Pfizer Boasts Strong Oncology Portfolio: Can it Sustain Growth? (Zacks)
12:05AM	2 Reasons to Watch MRK and 1 to Stay Cautious (StockStory)
Jun-18-25 05:45PM	Why the Market Dipped But Merck (MRK) Gained Today (Zacks)
12:46PM	Zoetis Stock Is Falling. Why the Animal-Health Company Was Downgraded. (Barrons.com)
10:00AM	Trump administration weighs crackdown on pharma ads, Bloomberg says (TipRanks)
09:18AM	Zoetis downgraded amid slowing growth concerns, intensifying competition (Investing.com)
09:13AM	American Kidney Fund Launches Kidney Cancer Education Campaign (GlobeNewswire)
07:00AM	IDeate-Prostate01 Phase 3 Trial of Ifinatamab Deruxtecan Initiated in Patients with Pretreated Metastatic Castration-Resistant Prostate Cancer (Business Wire)
05:02AM	2 Dividend Stocks to Buy and Never Sell (Motley Fool)
03:11AM	Dividend Growth Remains a Key Priority for Merck (Insider Monkey)
Jun-17-25 05:50PM	Merck (MRK) Dips More Than Broader Market: What You Should Know (Zacks)
02:39PM	Slowing Gardasil Sales Hurt MRK's Top Line: Is Recovery in the Cards? (Zacks)
11:20AM	Cantor Keeps Merck (MRK) at Neutral Amid Gardasil Dosage Review By ACIP. (Insider Monkey)
08:04AM	Exiger CMO Kody Gurfein Wins PRNews' Top Women Award (PR Newswire)
Jun-16-25 09:30AM	Wall Street Bulls Look Optimistic About Merck (MRK): Should You Buy? (Zacks)
Jun-15-25 05:47AM	Goldman Sachs Remains a Buy on Merck & Co (MRK), Sets a $99.00 PT (Insider Monkey)
Jun-14-25 08:02AM	These Were the 2 Worst-Performing Stocks in the Dow Jones Industrial Average in May 2025 (Motley Fool)
Jun-13-25 07:31PM	RFK Jr. Appointee To CDC Advisory Committee Was A Paid Expert In Merck's Gardasil Lawsuit (Benzinga)
12:45PM	Senators to propose ban on drug ads to consumers, WSJ reports (TipRanks)
11:00AM	Citizens Financial, Merck, oil producers: Trending Tickers (Yahoo Finance Video)
09:47AM	BMY Focuses on Label Expansion of Drugs: Will This Revive Growth? (Zacks)
07:00AM	Investors should be 'embracing volatility' (Yahoo Finance Video)
06:45AM	FDA Approves KEYTRUDA (pembrolizumab) for PD-L1+ Resectable Locally Advanced Head & Neck Squamous Cell Carcinoma as Neoadjuvant Treatment, Continued as Adjuvant Treatment Combined With Radiotherapy With or Without Cisplatin Then as a Single Agent (Business Wire)
05:31AM	MSD begins Phase III trial of dengue vaccine (Clinical Trials Arena)
Jun-12-25 04:45PM	Merck Animal Health Receives EU CVMP Positive Opinion for NUMELVI (atinvicitinib) Tablets for Dogs (Business Wire)
10:21AM	PFE's New & Acquired Drugs Hold Key to Revenue Growth Amid Headwinds (Zacks)
06:45AM	Merck Initiates Phase 3 Study Evaluating Dengue Vaccine Candidate (Business Wire)
Jun-11-25 05:45PM	Here's Why Merck (MRK) Fell More Than Broader Market (Zacks)
04:51PM	Merck's Cholesterol Medication Achieves Primary Endpoint in Two Trials (Insider Monkey)
11:30AM	Merck & Co (MRK) RSV Antibody for Infants Approved by US FDA (Insider Monkey)
10:20AM	Trump Trade: RFK Jr. removes members of vaccine-advising CDC panel (TipRanks)
09:36AM	JNJ vs. MRK: Which Healthcare Titan Offers Better Growth Prospects? (Zacks)
05:41AM	Should You Buy the 3 Highest-Paying Dividend Stocks in the Dow Jones? (Motley Fool)
Jun-10-25 08:02PM	Analyst Report: Merck & Co., Inc. (Morningstar Research)
05:50PM	Merck (MRK) Rises Higher Than Market: Key Facts (Zacks)
10:50AM	Merck Secures FDA Nod for New RSV Antibody Enflonsia in Infants (Zacks)
09:46AM	Will Merck's Keytruda Continue to Drive Growth Amid Looming LOE? (Zacks)
08:18AM	Why Moderna, Pfizer Stocks Are Shrugging Off RFK Jr.'s Firing of Vaccine Advisors. (Barrons.com)
Jun-09-25 03:11PM	U.S. FDA Approves Mercks ENFLONSIA (clesrovimab-cfor) for Prevention of Respiratory Syncytial Virus (RSV) Lower Respiratory Tract Disease in Infants Born During or Entering Their First RSV Season (Business Wire)
02:15PM	Merck's Cholesterol Lowering Drug Hits Primary Goal In Two Pivotal Trials (Benzinga)
12:03PM	Merck antibody drug for RSV approved by FDA (BioPharma Dive)
11:08AM	Merck Pill Lowers Cholesterol Levels. By How Much Is the Critical Point. (Barrons.com)
06:45AM	Merck Announces Positive Topline Results From the First Two Phase 3 CORALreef Trials Evaluating Enlicitide Decanoate for the Treatment of Adults With Hyperlipidemia (Business Wire)
05:05AM	Merck claims study success with PCSK9 cholesterol pill (BioPharma Dive)
Jun-07-25 04:30AM	Should You Buy the 3 Highest-Paying Dividend Stocks in the Dow Jones? (Motley Fool)
Jun-06-25 04:16PM	Challenges pharma companies face in push into US manufacturing (Yahoo Finance Video)
09:16AM	BMY Collaborates for Oncology Drug: Will This Boost Its Portfolio? (Zacks)
Jun-05-25 11:28AM	RDY & ALVO Ink Collaboration Deal for Merck's Keytruda Biosimilar (Zacks)
09:19AM	Analyst Says Merck (MRK) is 'Really Cheap' But Warns About Potential 'Bad News' (Insider Monkey)
Jun-04-25 05:45PM	Merck (MRK) Outpaces Stock Market Gains: What You Should Know (Zacks)
12:06PM	MLTX Stock Gains 18% as Merck Reportedly Eyes Buyout (Zacks)
12:03PM	Daiichi Sankyo struck gold with ADC cancer drugs. Its new CEO has to figure out whats next. (BioPharma Dive)
10:18AM	Exelixis Stock Surges 28% YTD: Should You Buy Now or Sell? (Zacks)
08:55AM	PGR institution likely weakens Halozyme bull case scenario, says Wells Fargo (TipRanks)
08:50AM	Merck granted review of Halozyme patent claims by PTAB (TipRanks)
06:45AM	Merck to Participate in the 46th Annual Goldman Sachs Global Healthcare Conference (Business Wire)
Jun-03-25 09:33AM	Constellation and Meta, Merck, Snowflake: Trending Tickers (Yahoo Finance Video)
09:27AM	MoonLake Immunotherapeutics Catapults On Rumored $3 Billion Merck Takeover Bid (Investor's Business Daily)
07:38AM	Merck's Dealmaking Intensifies With MoonLake Bid As Keytruda Patent Cliff Nears: Report (Benzinga)
06:30AM	Bristol Myers Paying BioNTech Up to $11.1B in Cancer Drug Team-up (The Daily Upside)
Jun-02-25 11:46AM	Summit Therapeutics Stock Nosedives on Mixed NSCLC Study Results (Zacks)
10:53AM	MRK's ADC Drug Combo Shows Antitumor Activity in Lymphoma Study (Zacks)
09:38AM	Gilead Reports Positive Data From Trodelvy, Keytruda Combo Study (Zacks)
09:22AM	Are Options Traders Betting on a Big Move in Merck Stock? (Zacks)
08:46AM	Bristol Myers makes $11 billion deal with BioNTech to join the cancer-drug race (MarketWatch)
02:45AM	Bristol Myers allies with BioNTech on bispecific cancer drug (BioPharma Dive)
May-31-25 08:00AM	KEYTRUDA (pembrolizumab) Plus Trodelvy (sacituzumab govitecan-hziy) Reduced Risk of Disease Progression or Death by 35% Versus KEYTRUDA Plus Chemotherapy in First-Line PD-L1+ Metastatic Triple-Negative Breast Cancer (TNBC) (Business Wire)
May-30-25 12:43PM	ASCO25: MSDs ADC candidate achieves 56.3% ORR in lymphoma trial (Clinical Trials Arena)

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Smart Dalton E. III	SVP Fin. - Global Controller	May 03 '25	Option Exercise	83.18	2,050	170,519	10,127	May 05 04:23 PM
Smart Dalton E. III	SVP Fin. - Global Controller	Apr 30 '25	Option Exercise	84.71	464	39,305	8,242	May 02 04:18 PM
Smart Dalton E. III	SVP Fin. - Global Controller	May 02 '25	Option Exercise	83.26	381	31,722	8,464	May 02 04:18 PM
Romanelli Joseph	President, Human Health Int?l	May 02 '25	Option Exercise	83.26	2,262	188,334	24,061	May 02 04:14 PM
Romanelli Joseph	President, Human Health Int?l	Apr 30 '25	Option Exercise	84.71	2,063	174,757	22,816	May 02 04:14 PM
Larson Betty D	EVP, Chief HR Officer	Apr 30 '25	Option Exercise	84.71	11,350	961,458	11,350	May 02 04:12 PM
Smart Dalton E. III	SVP Fin. - Global Controller	Apr 25 '25	Option Exercise	58.08	5,000	290,400	12,040	Apr 29 04:04 PM
Smart Dalton E. III	SVP Fin. - Global Controller	Apr 25 '25	Sale	82.76	4,262	352,723	7,778	Apr 29 04:04 PM
DALTON SMART	Officer	Apr 25 '25	Proposed Sale	82.76	4,262	352,723		Apr 25 04:05 PM
Oosthuizen Johannes Jacobus	President, U.S. Market	Feb 19 '25	Sale	84.09	8,500	714,745	30,705	Feb 20 04:01 PM
JOHANNES JACOBUS OOSTHUIZEN	Officer	Feb 19 '25	Proposed Sale	84.09	8,500	714,745		Feb 19 05:09 PM
DAVID WILLIAMS	Officer	Feb 13 '25	Proposed Sale	85.34	6,000	512,057		Feb 13 04:10 PM
Williams David Michael	EVP,Chief Info&Digital Officer	Feb 13 '25	Sale	85.34	6,000	512,057	24,123	Feb 13 04:01 PM
Oosthuizen Johannes Jacobus	President, U.S. Market	Feb 08 '25	Option Exercise	87.28	13,002	1,134,815	45,609	Feb 11 02:59 PM
THULIN INGE G	Director	Feb 06 '25	Buy	88.25	2,833	250,000	2,933	Feb 07 04:09 PM
Downing Cristal N	Chief Comm. & Public Afrs Ofcr	Feb 06 '25	Sale	88.76	2,361	209,551	7,085	Feb 07 04:07 PM
BAKER DOUGLAS M JR	Director	Feb 05 '25	Buy	88.50	15,000	1,327,500	16,000	Feb 07 04:04 PM
CRISTAL DOWNING	Officer	Feb 06 '25	Proposed Sale	88.76	2,361	209,551		Feb 06 04:43 PM
Guindo Chirfi	Chief Marketing Officer	Aug 05 '24	Option Exercise	115.20	36,901	4,250,995	57,782	Aug 06 12:20 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

MRK

Merck & Co Inc

Upgrade your FINVIZ experience